Chen Lin, MD
Allergy & Immunology · Katy, TXNPI 1881960573
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by CSL Behring at 49.2% of the total. 2025 is the largest year on record at $12,184, more than ten times the $481 reported in 2019.
Across 168 payments — averaging $110.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$9K
- Sanofi$3K
- Blueprint Medicines Corporation$3K
- Takeda Pharmaceuticals U.S.A., Inc.$555
- AstraZeneca$537
- GSK$453
- plus $2K from 21 others
What the payments were for
- Consulting fees$9,62852%
- Speaking & faculty fees$1,82410%
- Travel & lodging$1,1396%
- Food & beverage$5,73331%
- Education$2531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 15 | $9,135 |
| Sanofi | 20 | $2,853 |
| Blueprint Medicines Corporation | 10 | $2,570 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $555 |
| AstraZeneca(2 entities) | 12 | $537 |
| GSK | 11 | $453 |
| Regeneron Healthcare Solutions, Inc. | 11 | $373 |
| Pharming Healthcare, Inc. | 10 | $358 |
| Sanofi Pasteur Inc. | 5 | $286 |
| Arcutis Biotherapeutics, Inc. | 3 | $276 |
| Novartis | 7 | $185 |
| Octapharma USA, Inc. | 3 | $156 |
| Grifols USA, LLC | 7 | $134 |
| Biocryst US Sales Co., LLC | 7 | $129 |
| Alk-abello, Inc | 5 | $110 |
| Shire North American Group Inc | 3 | $73 |
| Amgen | 1 | $65 |
| GC Biopharma USA, Inc. | 2 | $57 |
| Fresenius Kabi USA, LLC | 2 | $53 |
| Lilly USA, LLC | 2 | $48 |
| Biocryst Pharmaceuticals, Inc. | 2 | $45 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $35 |
| Galderma Laboratories, L.p. | 1 | $26 |
| Abbott | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,578 in reported general payments places this provider in the 80th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 12 | $923,054 |
| XolairOmalizumab | 25 | $82,851 |
| IcatibantIcatibant Acetate | 12 | $54,761 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,541 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 13 | $2,033 |
| Cromolyn Sodium | 15 | $1,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $555 | $923,05412 claims |
| GSKTrelegy Ellipta | $453 | $10,54117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Katy
- Pardeep RihalKaty$85K
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Lara GrossDallas$171K
- Bobby LanierBenbrook$149K
- Juan ZambranoHouston$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.